Oxcarbazepine
Product Images NDC 50268-649

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 50268-649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (649 30)

This is information regarding Oxcarbazepine Oral Suspension. It contains 300 mg of oxcarbazepine per 5 mL. The medication should be used within 7 weeks of opening. It is important to shake well before using. The recommended storage is in the original container at 20 to 25°C (68 to 77°F). Excursions are permitted between 15 to 30°C (59 to 85°F). Keep all drugs out of the reach of children. The product is manufactured for AKAFE in Pulaski, TN 38478.*

FDA Label Image

9f14a9c2-figure-01 (Oxcarbazepine Oral Suspension Usp 1)

FDA Label Image

9f14a9c2-figure-02 (Oxcarbazepine Oral Suspension Usp 2)

This text provides information on the treatment group being administered Oxcarbazepine. It mentions a time trial from Day 2 to Day 11 for evaluating the effectiveness of the treatment.*

FDA Label Image

9f14a9c2-figure-03 (Oxcarbazepine Oral Suspension Usp 3)

This text provides results from a log-rank test, indicating a p-value of 0.045. The data seems to be related to days from the 1st dose to the 1st seizure in two treatment groups: Oxcarbazepine and Placebo. The values for different time points and treatments are also listed.*

FDA Label Image

9f14a9c2-figure-04 (Oxcarbazepine Oral Suspension Usp 4)

This is a log-rank test result showing a p-value of 0.0001. The graph displays the time to exit in days for the treatment groups labeled as HIGH and LOW. The data points seem to be irregularly spaced at intervals of 10 to 20 days.*

FDA Label Image

9f14a9c2-figure-05 (Oxcarbazepine Oral Suspension Usp 5)

This text provides the results of a statistical analysis using the log-rank test, showing a significant p-value of 0.0001. The data includes time to exit (in days) for two treatment groups: HIGH and LOW. The purpose of this analysis was likely to compare the survival times between the two treatment groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.